Literature DB >> 9074839

Choosing the right macrolide antibiotic. A guide to selection.

L Charles1, J Segreti.   

Abstract

Macrolide antibiotics have proven to be valuable alternatives to penicillins and cephalosporins for the treatment of a number of infections. Currently, a number of macrolides are available. When choosing a particular macrolide, the types of organisms causing the infection, the tolerability of the drug, convenience of dosing and possible drug interactions all must be taken into account. Erythromycin, azithromycin and clarithromycin are equally effective against most gram-positive organisms. However, clarithromycin and azithromycin have much better activity against Haemophilus influenza and Moraxella catarrhalis. Thus, these 2 drugs are better choices for the treatment of community-acquired pneumonia. However, the low serum concentrations of azithromycin may be a problem in patients with bacteraemia associated with with community-acquired pneumonia. Clarithromycin appears to be effective for the treatment and prophylaxis of Mycobacterium avium complex (MAC) in patients with AIDS, while azithromycin appears to be effective for prophylaxis. Treatment of MAC with azithromycin is currently undergoing study. Although clarithromycin is the macrolide of choice for the treatment of Helicobacter pylori, azithromycin is the preferred macrolide for the treatment of Chlamydia trachomatis infections. The major factor limiting the use of azithromycin and clarithromycin has been their cost. However, these drugs may be cost effective if compliance is improved due to better tolerability and more convenient dosing regimens.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9074839     DOI: 10.2165/00003495-199753030-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  99 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex.

Authors:  C B Inderlied; P T Kolonoski; M Wu; L S Young
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

3.  Azithromycin in the treatment of sexually transmitted disease.

Authors:  O Steingrimsson; J H Olafsson; H Thorarinsson; R W Ryan; R B Johnson; R C Tilton
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  Clarithromycin vs. amoxicillin suspensions in the treatment of pediatric patients with acute otitis media.

Authors:  J S Pukander; J P Jero; E A Kaprio; M J Sorri
Journal:  Pediatr Infect Dis J       Date:  1993-12       Impact factor: 2.129

Review 6.  The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease.

Authors:  N Vakil; B Fennerty
Journal:  Am J Med       Date:  1996-05-20       Impact factor: 4.965

7.  A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.

Authors:  A I Hoepelman; A P Sips; J L van Helmond; P W van Barneveld; A J Neve; M Zwinkels; M Rozenberg-Arska; J Verhoef
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

8.  In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence.

Authors:  M Bonnet; P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.

Authors:  B O'Brien; R Goeree; A H Mohamed; R Hunt
Journal:  Arch Intern Med       Date:  1995-10-09

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more
  4 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500mg Once Daily for 3 Days.

Authors:  F Crokaert; A Hubloux; P Cauchie
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

4.  Erythromycin decreases the time and improves the quality of EGD in patients with acute upper GI bleeding.

Authors:  Mohammad Javad Ehsani Ardakani; Ehsan Zare; Maryam Basiri; Hamid Mohaghegh Shalmani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2013
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.